Search clinical trials for: Placebo for MK-8150

Total 3058 results

Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)

Hypertension | Isolated Systolic Hypertension
Merck Sharp & Dohme LLC

Completed

A Single Rising Dose Study of MK-8150 (MK-8150-001)

Hypertension | Isolated Systolic Hypertension (ISH)
Merck Sharp & Dohme LLC

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study of MK-3614 (MK-3614-002)

Hypertension
Merck Sharp & Dohme LLC

Completed

A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)

Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC

Completed

A Study of the Effect of MK-8457 on Blood Pressure in Hypertensive Participants (MK-8457-004-AM1)

Hypertension

United States
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma

Asthma

United States, Australia, New Zealand, South Africa
Merck Sharp & Dohme LLC

Completed

A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)

Asthma
Merck Sharp & Dohme LLC

Recruiting

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

Heart Failure | Left Ventricular Systolic Dysfunction

Korea, Republic of, United States, France, Finland, Portugal, Sweden, Denmark, Spain, Turkey, Hungary, Netherlands, Ireland, Malaysia, Colombia, Germany, Singapore, Thailand, Italy, New Zealand, Belgium, Brazil, Canada, United Kingdom
Merck Sharp & Dohme LLC
Bayer; Duke Clinical Research Institute; Canadian VIGOUR Centre

Completed

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) (VICTORIA)

Heart Failure | Chronic Heart Failure With Reduced Ejection Fraction
Merck Sharp & Dohme LLC

Completed

A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)

Rosacea
Merck Sharp & Dohme LLC

Completed

A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)

Urinary Incontinence
ALK-Abelló A/S

Completed

A Study of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet in Adults With Ragweed Allergies (P05751)

Allergy
Afferent Pharmaceuticals, Inc.

Completed

A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough (MK-7264-010)

Refractory Chronic Cough
Afferent Pharmaceuticals, Inc.

Completed

An 8-Week Refractory Chronic Cough Study (MK-7264-021)

Refractory Chronic Cough

United States
Merck Sharp & Dohme LLC

Completed

Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)

Non-alcoholic Fatty Liver Disease
National Institute of Allergy and Infectious Diseases...
AbbVie

Active, not recruiting

A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

HIV-1-infection

United States
Merck Sharp & Dohme LLC

Withdrawn

MK-8510 Monotherapy for the Treatment of Anti-retroviral naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants (MK-8510-002)

HIV-1 | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1 | Human Immunodeficiency Virus 1
Afferent Pharmaceuticals, Inc.

Completed

A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)

Refractory Chronic Cough
Merck Sharp & Dohme LLC

Completed

A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)

Polysomnography
Merck Sharp & Dohme LLC

Recruiting

A Study of the Efficacy and Safety of MK-5475 in Participants With Pulmonary Arterial Hypertension (INSIGNIA-PAH: Phase 2/3 Study of an Inhaled sGC Stimulator in PAH) (MK-5475-007)

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States, Argentina, Australia, Belgium, Canada, Colombia, France, Germany, Israel, Italy, Mexico, New Zealand, Poland, Sweden, Turkey, United Kingdom, Greece, Russian Federation
Merck Sharp & Dohme LLC

Recruiting

Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)

HIV | HIV Pre-exposure Prophylaxis

United States, South Africa, Israel
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)

Hepatitis C
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)

Ulcerative Colitis

United States, Georgia, Germany, Hungary, Moldova, Republic of, Poland, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Completed

A Single Dose Study of MK-8266 (MK-8266-001)

Hypertension
Merck Sharp & Dohme LLC

Completed

Polysomnography Study of MK-6096 in Participants With Primary Insomnia (MK-6096-011)

Primary Insomnia
Merck Sharp & Dohme LLC

Withdrawn

A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)

Asthma
Merck Sharp & Dohme LLC

Completed

Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)

HIV-1 Infection

United States, Australia, Canada, Chile, Colombia, France, Germany, Italy, Japan, Korea, Republic of, Peru, Portugal, Puerto Rico, Russian Federation, South Africa, Spain, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-8189 in Participants With Bipolar I Disorder (MK-8189-020)

Bipolar I Disorder

United States
Merck Sharp & Dohme LLC

Recruiting

A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)

Non-segmental Vitiligo

United States, Canada, Australia, Korea, Republic of, Switzerland, Germany, Spain, Chile, France, Israel, Netherlands, Japan, Belgium
Merck Sharp & Dohme LLC

Completed

A Study of Single Doses of MK -5475 on Pulmonary Vascular Resistance (MK-5475-002)

Pulmonary Arterial Hypertension

Moldova, Republic of
Merck Sharp & Dohme LLC

Completed

MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)

Alzheimer's Disease

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001)

Cancer | Pharmacokinetics

Belgium
Merck Sharp & Dohme LLC

Completed

A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)

Migraine | Headache
Merck Sharp & Dohme LLC

Completed

Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)

Depression
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Terminated

A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8325 in Hepatitis C-Infected Males (MK-8325-002)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Recruiting

Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)

Narcolepsy

United States
Merck Sharp & Dohme LLC

Recruiting

Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)

Systemic Lupus Erythematosus

United States, Canada, Japan, Chile, France, Poland, Spain, Guatemala, Italy
Merck Sharp & Dohme LLC

Recruiting

MK-5475-013 INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of MK-5475 (an Inhaled sGC Stimulator) in Adults With PH-COPD

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States, Korea, Republic of, Australia, Germany, Spain, Italy, Switzerland, France, Argentina, Colombia, Israel, Austria, Mexico, United Kingdom, Belgium, Turkey, Peru, South Africa
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-2214 in Adults With Mild Cognitive Impairment or Mild-to-Moderate Alzheimer's Disease (MK-2214-002)

Alzheimer Disease

United States
Merck Sharp & Dohme LLC

Completed

MK-5475 in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)

Pulmonary Hypertension

United States, Israel, Moldova, Republic of
Merck Sharp & Dohme LLC

Completed

A Study of MK-8189 in Participants With Schizophrenia (MK-8189-014)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and Healthy Participants (MK-8189-011)

Schizophrenia

United States
Merck Sharp & Dohme LLC

Withdrawn

MK-5475 in Participants With Hypoxemia Due to COVID-19 Pneumonia (MK-5475-009)

Pneumonia | Coronavirus Disease 2019 (COVID-19) | Hypoxemia
Merck Sharp & Dohme LLC

Completed

The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)

Postherpetic Neuralgia

3

Subscribe